Metallothionein overexpression in human brain tumours

Hans Maier, Chris Jones, Bharat Jasani, Dietmar Öfner, Bettina Zelger, Kurt Werner Schmid, Herbert Budka

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal tumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other tumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7%) showed MT expression of more than 25% of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain tumours and might be involved in their poor response to antineoplastic drugs.

Original languageEnglish
Pages (from-to)599-604
Number of pages6
JournalActa Neuropathologica
Volume94
Issue number6
DOIs
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Metallothionein
Meningioma
Brain Neoplasms
Glioma
Neoplasms
Meningeal Neoplasms
Hemangiopericytoma
Glioblastoma
Antineoplastic Agents
Carrier Proteins
Western Blotting
Metals
Pharmaceutical Preparations

Keywords

  • Gliomas
  • Immunohistochemistry
  • Meningiomas
  • Metallothioneins

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Maier, H., Jones, C., Jasani, B., Öfner, D., Zelger, B., Schmid, K. W., & Budka, H. (1997). Metallothionein overexpression in human brain tumours. Acta Neuropathologica, 94(6), 599-604. https://doi.org/10.1007/s004010050755

Metallothionein overexpression in human brain tumours. / Maier, Hans; Jones, Chris; Jasani, Bharat; Öfner, Dietmar; Zelger, Bettina; Schmid, Kurt Werner; Budka, Herbert.

In: Acta Neuropathologica, Vol. 94, No. 6, 1997, p. 599-604.

Research output: Contribution to journalArticle

Maier, H, Jones, C, Jasani, B, Öfner, D, Zelger, B, Schmid, KW & Budka, H 1997, 'Metallothionein overexpression in human brain tumours', Acta Neuropathologica, vol. 94, no. 6, pp. 599-604. https://doi.org/10.1007/s004010050755
Maier H, Jones C, Jasani B, Öfner D, Zelger B, Schmid KW et al. Metallothionein overexpression in human brain tumours. Acta Neuropathologica. 1997;94(6):599-604. https://doi.org/10.1007/s004010050755
Maier, Hans ; Jones, Chris ; Jasani, Bharat ; Öfner, Dietmar ; Zelger, Bettina ; Schmid, Kurt Werner ; Budka, Herbert. / Metallothionein overexpression in human brain tumours. In: Acta Neuropathologica. 1997 ; Vol. 94, No. 6. pp. 599-604.
@article{c489b2ae07c5415f91b5c1b8f3153d35,
title = "Metallothionein overexpression in human brain tumours",
abstract = "Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal tumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other tumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7{\%}) showed MT expression of more than 25{\%} of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain tumours and might be involved in their poor response to antineoplastic drugs.",
keywords = "Gliomas, Immunohistochemistry, Meningiomas, Metallothioneins",
author = "Hans Maier and Chris Jones and Bharat Jasani and Dietmar {\"O}fner and Bettina Zelger and Schmid, {Kurt Werner} and Herbert Budka",
year = "1997",
doi = "10.1007/s004010050755",
language = "English",
volume = "94",
pages = "599--604",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Metallothionein overexpression in human brain tumours

AU - Maier, Hans

AU - Jones, Chris

AU - Jasani, Bharat

AU - Öfner, Dietmar

AU - Zelger, Bettina

AU - Schmid, Kurt Werner

AU - Budka, Herbert

PY - 1997

Y1 - 1997

N2 - Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal tumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other tumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7%) showed MT expression of more than 25% of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain tumours and might be involved in their poor response to antineoplastic drugs.

AB - Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal tumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other tumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7%) showed MT expression of more than 25% of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain tumours and might be involved in their poor response to antineoplastic drugs.

KW - Gliomas

KW - Immunohistochemistry

KW - Meningiomas

KW - Metallothioneins

UR - http://www.scopus.com/inward/record.url?scp=0030813197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030813197&partnerID=8YFLogxK

U2 - 10.1007/s004010050755

DO - 10.1007/s004010050755

M3 - Article

VL - 94

SP - 599

EP - 604

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 6

ER -